Table 2.
Effect of thymoquinone loaded PLGA nanoparticles on locomotor activity, grip strength, and cerebral infract volume in the MCAO rats.
| Groups | Treatment | Locomotor activity (count/5 min) |
Grip strength (Kg/unit) |
Infarct volume (mm3)# |
|---|---|---|---|---|
| 1 | Sham control | 21.62 ± 0.312 | 0.68 ± 0.053 | — |
| 2 | MCAO control | 3.54 ± 0.021¶¶ | 0.12 ± 0.03¶¶ | 76.28 ± 0.112 |
| 3 | MCAO + TQ PLGA NPs (i.n.) |
16.89 ± 0.218∗∗ | 0.36 ± 0.087∗ | 38.34 ± 0.123∗ |
| 4 | MCAO + TQ solution (i.n.) |
15.12 ± 0.093∗ | 0.19 ± 0.101 | 45.19 ± 0.091 |
| 5 | MCAO + TQ solution (oral) |
9.23 ± 0.101∗ | 0.23 ± 0.214∗ | 44.78 ± 0.153 |
The intranasal delivery of TQ-PLGA nanoparticles led to significant increase in the locomotor activity and grip strength and decrease in ischemia infarct volume in the MCAO rats when compared to TQ solution delivered by intranasal or oral route alone. N = 12 (# N = 6); data represent mean ± SEM; ¶¶ P < 0.01 versus sham control; ∗∗ P < 0.01 versus MCAO control; and ∗ P < 0.05 versus MCAO control.